Zimmer Biomet (NYSE: ZBH) announced today that it appointed Kevin Thornal as group president, global businesses and the Americas.
Thornal will report to President and CEO Ivan Tornos and join the company on July 1, 2025. His responsibilities include overseeing the Americas commercial organization. He also leads business strategy and execution for global Knee, Hip, S.E.T. and Data, Technology and Enabling Solutions units.
“Kevin is an incredible addition to our leadership team at an exciting time for our company,” said Tornos. “He brings a bold desire to win and a demonstrated track record of delivering consistently strong growth, driving commercial excellence and building high-performing teams. I am confident his breadth and depth of experience will serve us well as we work together to elevate our U.S. performance and commercial execution, deliver value for all stakeholders, and advance our Mission of alleviating pain and improving the quality of life for people around the world.”
[For more on the orthopedic device space, see our recent special report.]
Thornal brings more than 20 years of medtech experience to the orthopedic giant. Most recently, he served as CEO and president of Nevro, which fellow orthopedic giant Globus Medical acquired earlier this year. Prior to that, Thornal spent nine years at Hologic, culminating in the post of group president of global Diagnostic Solutions.
While at Hologic, Thornal led the Diagnostic Solutions division during the COVID-19 pandemic. He also oversaw global teams in R&D, operations and commercial as the company launched new products and expanded its footprint.
Thornal brings experience in orthopedics, too, having spent a decade in roles of increasing responsibility at Stryker. There, he served as head of North American sales for Stryker’s Interventional Spine business.
“I could not be more excited to return to orthopedics and join Zimmer Biomet on the journey to becoming the boldest company in medical technology,” said Thornal. “There’s a tremendous opportunity to address key unmet needs in musculoskeletal health by helping more customers and patients access the company’s robust new product pipeline. I look forward to working with this talented team, contributing to Zimmer Biomet’s culture of collaboration and innovation and delivering meaningful outcomes for patients and customers around the world.”
